Advertisement

APBI with 50 kV Photons: Targeted Intraoperative Radiotherapy (TARGIT)

  • Jayant S. Vaidya

Whole-organ analysis of mastectomy specimens vis-à-vis the results of breast-conserving surgery trials suggests that clinically important breast cancer is a regional disease. A “geographical miss” of the tumor bed boost can occur in 50–79% of cases and could contribute considerably to local recurrence. A “temporal miss” (a crucial delay in delivering radiotherapy) is most likely to occur in the few hours/days immediately after surgery when the tumor bed bathes in wound fluid. Translational research has shown that TARGIT abrogates the potentially harmful effects of wound fluid. The results of the START trials corroborate with our mathematical models of TARGIT and suggest that single high doses delivered accurately might be superior to multiple fractions of smaller doses. Targeting radiotherapy to the tumor bed means that it can be delivered accurately at the time of surgery, does not delay adjuvant chemotherapy, and could allow breast-conserving surgery (rather than mastectomy) when a long postoperative course of radiotherapy is not desirable or practical.

With our TARGIT approach (pioneered in 1998), a single fraction of 20 Gy is delivered to the surface of the tumor bed, in the cavity produced by the excision of tumor tissue, using a spherical applicator (the Intrabeam system; Carl Zeiss Meditec, Germany), while the patient is anesthetized for primary surgery. TARGIT can also be delivered as a second procedure and even under local anesthetic because, unlike the Novac7 system being used in the Italian ELIOT trial, TARGIT does not require extensive dissection of skin flaps and the chest wall away from the breast disc. The TARGIT technique uses low-energy X-rays (50 kV); hence, unlike other methods of PBI, the volume of tissue that receives very high doses of radiation is small, which means that external-beam whole breast radiotherapy (EBRT) can be added without causing acute or long-term toxicity. The heart and the lungs do not receive any significant irradiation during TARGIT application. In addition, unlike MammoSite (Cytyc Corp., Marlborough, MA, USA), TARGIT does not require complicated CT planning, and patients do not become ineligible on the basis of having particular tumor locations. The cost of delivering TARGIT, the most economical method of PBI, is considerably less than that associated with the use of a linear accelerator, which it could potentially replace for a significant proportion of patients.

The technique itself has FDA approval and the CE mark for clinical use in any part of the body. The use of TARGIT as the sole treatment in low-risk patients over 45 years, instead of the usual 3–6 week postoperative EBRT course, is being tested in the TARGIT-A trial launched in March 2000 and which is currently recruiting in 22 centers worldwide. TARGIT is already being used as a standard boost technique in many centers and is included in the German national guidelines. Updated results (ASCO2008) for the 300 unselected patients treated in five international centers using TARGIT as a boost treatment followed by EBRT demonstrated a very low five-year actuarial recurrence rate of 1.52%, despite having a relatively high-risk patient population (29% were node positive, and a third were younger than 51 and grade 3). The TARGIT-B trial, which has just started recruitment, will test whether the TARGIT boost is indeed superior in high-risk patients. The results of the TARGIT trials could usher in a novel individualized local treatment for breast cancer.

Keywords

Breast Cancer Radiat Oncol Biol Phys Ipsilateral Breast Tumor Recurrence Partial Breast Irradiation Early Breast Cancer Trialist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Astor MB, Hilaris BS, Gruerio A, Varricchione T, Smith D (2000) Preclinical studies with the photon radiosurgery system (PRS). Int J Radiat Oncol Biol Phys 47:809–813PubMedCrossRefGoogle Scholar
  2. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR (2000) Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst 92:269–271PubMedCrossRefGoogle Scholar
  3. Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pelegrin A (2005) Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 7:R156–R163PubMedCrossRefGoogle Scholar
  4. Baldassarre G, Belleti B, Vaidya JS, D'Andrea S, Roncadin M, Perin T, Trova MG, Candiani E, Veronesi A, Colombatti A, Massarut S (2007) Intraoperative radiotherapy (IORT) impairs surgical wound-stimulated breast cancer cell invasion. J Clin Oncol 25:21139Google Scholar
  5. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, the European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRefGoogle Scholar
  6. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den BW, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25(22):3259–3265PubMedCrossRefGoogle Scholar
  7. Bates T, Evans RG (1995) Audit of brachial plexus neuropathy following radiotherapy. Clin Oncol (R Coll Radiol) 7:236Google Scholar
  8. Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovo MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S (2008) Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 14:1325–1332PubMedCrossRefGoogle Scholar
  9. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008a) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371:1098–1107CrossRefGoogle Scholar
  10. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR (2008b) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet 371(9618):1098–1107CrossRefGoogle Scholar
  11. Brenner DJ, Leu CS, Beatty JF, Shefer RE (1999) Clinical relative biological effectiveness of lowenergy X-rays emitted by miniature X-ray devices. Phys Med Biol 44:323–333PubMedCrossRefGoogle Scholar
  12. Chan DY, Koniaris L, Magee C, Ferrell M, Solomon S, Lee BR, Anderson JH, Smith DO, Czapski J, Deweese T, Choti MA, Kavoussi LR (2000) Feasibility of ablating normal renal parenchyma by interstitial photon radiation energy: study in a canine model. J Endourol 14:111–116PubMedCrossRefGoogle Scholar
  13. Clark RM, Wilkinson RH, Mahoney LJ, Reid JG, MacDonald WD (1982) Breast cancer: a 21 year experience with conservative surgery and radiation. Int J Radiat Oncol Biol Phys 8:967–979PubMedGoogle Scholar
  14. Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ, Basrur VR, Nair BD, McDermot RS, Wong CS (1992) Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84:683–689PubMedCrossRefGoogle Scholar
  15. Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH, Mahoney LJ (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88:1659–1664PubMedCrossRefGoogle Scholar
  16. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499–505PubMedGoogle Scholar
  17. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS (1996) Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057–2059PubMedCrossRefGoogle Scholar
  18. Early Breast Cancer Trialists' Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333:1444–1455CrossRefGoogle Scholar
  19. Early Breast Cancer Trialists' Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355:1757–1770CrossRefGoogle Scholar
  20. Enderling H, Anderson AR, Chaplain MA, Munro AJ, Vaidya JS (2006) Mathematical modelling of radiotherapy strategies for early breast cancer. J Theor Biol 241:158–171PubMedCrossRefGoogle Scholar
  21. Enderling H, Chaplain MA, Anderson AR, Vaidya JS (2007) A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol 246:245–259PubMedCrossRefGoogle Scholar
  22. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer (see comments). N Engl J Med 333:1456–1461PubMedCrossRefGoogle Scholar
  23. Flickinger JC, Kondziolka D, Lunsford LD (1995) Radiosurgery of benign lesions. Semin Radiat Oncol 5:220–224PubMedCrossRefGoogle Scholar
  24. Flickinger JC, Kondziolka D, Lunsford LD (2003) Radiobiological analysis of tissue responses following radiosurgery. Technol Cancer Res Treat 2:87–92PubMedGoogle Scholar
  25. Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, Smith DC, George WD (1996) Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group (see comments). Lancet 348:708–713PubMedCrossRefGoogle Scholar
  26. Halsted WS (1894) The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Hospital Reports 4:297–350Google Scholar
  27. Herskind C, Steil V, Kraus-Tiefenbacher U, Wenz F (2005) Radiobiological aspects of intraoperative radiotherapy (IORT) with isotropic low-energy X rays for early-stage breast cancer. Radiat Res 163:208–215PubMedCrossRefGoogle Scholar
  28. Herskind C, Schalla S, Hahn EW, Hover KH, Wenz F (2006) Infl uence of different dose rates on cell recovery and RBE at different spatial positions during protracted conformal radiotherapy. Radiat Prot Dosimetry 122:498–505PubMedCrossRefGoogle Scholar
  29. Herskind C, Griebel J, Kraus-Tiefenbacher U, Wenz F (2008) Sphere of equivalence—a novel target volume concept for intraoperative radiotherapy using low-energy X rays. Int J Radiat Oncol Biol Phys 72(5):1575–81PubMedGoogle Scholar
  30. Joseph DJ, Bydder S, Jackson LR, Corica T, Hastrich DJ, Oliver DJ, Minchin DE, Haworth A, Saunders CM (2004) Prospective trial of intraoperative radiation treatment for breast cancer. ANZ J Surg 74:1043–1048PubMedCrossRefGoogle Scholar
  31. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRefGoogle Scholar
  32. Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M (2005) Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 23:5526–5533PubMedCrossRefGoogle Scholar
  33. Keshtgar M, Tobias JS, Vaidya JS, Stacey C, Corica T, Joseph D, Keller A, Wenz F, Williams NR, Baum M (2008) Breast cancer patients treated with intra-operative radiotherapy alone when conventional external beam radiation therapy was not possible. Eur J Cancer Suppl 6:146–147CrossRefGoogle Scholar
  34. Koniaris LG, Chan DY, Magee C, Solomon SB, Anderson JH, Smith DO, De Weese T, Kavoussi LR, Choti MA (2000) Focal hepatic ablation using interstitial photon radiation energy. J Am Coll Surg 191:164–174PubMedCrossRefGoogle Scholar
  35. Kraus-Tiefenbacher U, Bauer L, Kehrer T, Hermann B, Melchert F, Wenz F (2006a) Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer: acute toxicity. Onkologie 29:77–82CrossRefGoogle Scholar
  36. Kraus-Tiefenbacher U, Bauer L, Scheda A, Fleckenstein K, Keller A, Herskind C, Steil V, Melchert F, Wenz F (2006b) Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery. Int J Radiat Oncol Biol Phys 66:377–381Google Scholar
  37. Kurita H, Ostertag CB, Baumer B, Kopitzki K, Warnke PC (2000) Early effects of PRS-irradiation for 9L gliosarcoma: characterization of interphase cell death. Minim Invasive Neurosurg 43:197–200PubMedCrossRefGoogle Scholar
  38. Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, Adami HO (1999) 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial (see comments). J Clin Oncol 17:2326–2333PubMedGoogle Scholar
  39. Lind DS, Kontaridis MI, Edwards PD, Josephs MD, Moldawer LL, Copeland EM (1997) Nitric oxide contributes to adriamycin's antitumor effect. J Surg Res 69:283–287PubMedCrossRefGoogle Scholar
  40. Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A (1996) Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional signifi cance of locally produced estrogen in human breast cancers. Endocrinology 137:3061–3068PubMedCrossRefGoogle Scholar
  41. Machtay M, Lanciano R, Hoffman J, Hanks GE (1994) Inaccuracies in using the lumpectomy scar for planning electron boosts in primary breast carcinoma. Int J Radiat Oncol Biol Phys 30:43–48PubMedGoogle Scholar
  42. Massarut S, Baldassare G, Belleti B, Reccanello S, D'Andrea S, Ezio C, Perin T, Reccanello S, Roncadin M, Vaidya JS (2006) Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fl uid. J Clin Oncol 24:10611Google Scholar
  43. McCulloch PG, MacIntyre A (1993) Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg 80:1005–1007PubMedCrossRefGoogle Scholar
  44. Meinardi MT, Van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, Van Den Berg MP, Volkers C, Haaksma J, De Vries EG, Sleijfer DT, Van Der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753PubMedGoogle Scholar
  45. Mikeljevic JS, Haward R, Johnston C, Crellin A, Dodwell D, Jones A, Pisani P, Forman D (2004) Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 90:1343–1348PubMedCrossRefGoogle Scholar
  46. Nakamura J, Savinov A, Lu Q, Brodie A (1996) Estrogen regulates vascular endothelial growth/ permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137:5589–5596PubMedCrossRefGoogle Scholar
  47. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA (1987) Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 56:814–819PubMedGoogle Scholar
  48. O'Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 296:741–743CrossRefGoogle Scholar
  49. Pawlik TM, Kuerer HM (2005) Accelerated partial breast irradiation as an alternative to whole breast irradiation in breast-conserving therapy for early-stage breast cancer. Women's Health 1:59–71CrossRefGoogle Scholar
  50. Reitsamer R, Peintinger F, Kopp M, Menzel C, Kogelnik HD, Sedlmayer F (2004) Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study. Strahlenther Onkol 180:38–44PubMedCrossRefGoogle Scholar
  51. Rutqvist LE, Johansson H (1990) Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 61:866–868PubMedGoogle Scholar
  52. Sedlmayer F, Rahim HB, Kogelnik HD, Menzel C, Merz F, Deutschmann H, Kranzinger M (1996) Quality assurance in breast cancer brachytherapy: geographic miss in the interstitial boost treatment of the tumor bed. Int J Radiat Oncol Biol Phys 34:1133–1139PubMedGoogle Scholar
  53. Solomon SB, Koniaris LG, Chan DY, Magee CA, DeWeese TL, Kavoussi LR, Choti MA (2001) Temporal CT changes after hepatic and renal interstitial radiotherapy in a canine model. J Comput Assist Tomogr 25:74–80PubMedCrossRefGoogle Scholar
  54. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRefGoogle Scholar
  55. Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations (see comments). J Clin Oncol 17:3017–3024PubMedGoogle Scholar
  56. Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG (2000) Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 88:1091–1098PubMedCrossRefGoogle Scholar
  57. Vaidya JS (2002) A novel approach for local treatment of early breast cancer. Ph.D. Thesis, University of London, London (see http://www.ucl.ac.uk/~rmhkjsv/papers/thesis.htm)Google Scholar
  58. Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I (1996) Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer 74:820–824PubMedGoogle Scholar
  59. Vaidya JS, Baum M, Tobias JS, Houghton J (1999) Targeted intraoperative radiotherapy (TARGIT) trial protocol. Lancet http://www.thelancet.com/protocol-reviews/99PRT-47
  60. Vaidya JS, Baum M, Tobias JS, D'souza DP, Naidu SV, Morgan S, Metaxas M, Harte KJ, Sliski AP, Thomson E (2001) Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 12:1075–1080PubMedCrossRefGoogle Scholar
  61. Vaidya JS, Baum M, Tobias JS, Morgan S, D'souza D (2002a) The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol 28:447–454CrossRefGoogle Scholar
  62. Vaidya JS, Baum M, Tobias JS, Morgan S, D'souza D (2002b) The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol 28:447–454CrossRefGoogle Scholar
  63. Vaidya JS, Hall-Craggs M, Baum M, Tobias JS, Falzon M, D'souza DP, Morgan S (2002c) Percutaneous minimally invasive stereotactic primary radiotherapy for breast cancer. Lancet Oncol 3:252–253CrossRefGoogle Scholar
  64. Vaidya JS, Joseph D, Hilaris BS, Tobias JS, Houghton J, Keshtgar M, Sainsbury R, Taylor I (2002d) Targeted intraoperative radiotherapy for breast cancer: an international trial. Abstract Book of ESTRO-21, Prague, Czech Republic, 18:21 Sept 2002, 21:135Google Scholar
  65. Vaidya JS, Wilson AJ, Houghton J, Tobias JS, Joseph D, Wenz F, Hilaris B, Massarut S, Keshtgar M, Sainsbury R, Taylor I, D'souza D, Saunders C, Corica T, Candiani E, Arcicasa M, Baum M (2003) Cosmetic outcome after targeted intraoperative radiotherapy (Targit) for early breast cancer. Breast Cancer Res Treat 82:1039Google Scholar
  66. Vaidya JS, Tobias J, Baum M, Keshtgar M, Houghton J, Wenz F, Corica T, Joseph D (2004a) Intraoperative radiotherapy: the debate continues. Lancet Oncol 5:339–340CrossRefGoogle Scholar
  67. Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'souza D, Sainsbury R, Massarut S, Taylor I, Hilaris B (2004b) Intraoperative radiotherapy for breast cancer. Lancet Oncol 5:165–173CrossRefGoogle Scholar
  68. Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Hilaris BS, Houghton J, Murphy O, Saunders C, Corica T, Harrison E, Keshtgar M, Douek M, Sainsbury R, Kraus-Tiefenbacher U, Melchart F, Joseph D (2005a) Targeted intraoperative radiotherapy (TARGIT) as a boost yields very low recurrence rates. Breast Cancer Res Treat 94:S180Google Scholar
  69. Vaidya JS, Tobias JS, Baum M, Wenz F, Kraus-Tiefenbacher U, D'souza D, Keshtgar M, Massarut S, Hilaris B, Saunders C, Joseph D (2005b) TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Semin Radiat Oncol 15:84–91CrossRefGoogle Scholar
  70. Vaidya JS, Baum M, Tobias JS, Massarut S, Wenz F, Murphy O, Hilaris B, Houghton J, Saunders C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Melchert F, Keshtgar M, Sainsbury R, Douek M, Harrison E, Thompson A, Joseph D (2006a) Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. Int J Rad Oncol Biol Phys 66:1335–1338Google Scholar
  71. Vaidya JS, Walton L, Dewar J (2006b) Single dose targeted intraoperative radiotherapy (TARGIT) for breast cancer can be delivered as a second procedure under local anaesthetic. World J Surg Oncol 4:2CrossRefGoogle Scholar
  72. Vaidya JS, Baum M, Tobias JS, Massarut S, Wenz F, Hilaris BS, Corica T, Roncadin M, KrausTiefenbacher U, Keshtgar M, Saunders C, Joseph D (2008) Efficacy of targeted intraoperative radiotherapy (Targit) boost after breast conserving surgery: updated results. J Clin Oncol 26:Abstr 565Google Scholar
  73. Vaidya JS, Baldassarre G, Massarut S (2009) Benefi cial effects of Intraoperative radiotherapy on tumour microenvironment could improve outcomes. Int J Radiat Oncol Biol Phys (in press)Google Scholar
  74. Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, Rilke F, Sacchini V, Saccozzi R, Savio T (1993) Radiotherapy after breast-preserving surgery in women with localized cancer of the breast (see comments). N Engl J Med 328:1587–1591PubMedCrossRefGoogle Scholar
  75. Wenz F, Steinvorth S, Wildermuth S, Lohr F, Fuss M, Debus J, Essig M, Hacke W, Wannenmacher M (1998) Assessment of neuropsychological changes in patients with arteriovenous malformation (AVM) after radiosurgery. Int J Radiat Oncol Biol Phys 42:995–999PubMedGoogle Scholar
  76. Wenz F, Welzel G, Keller A, Blank E, Vorodi F, Herskind C, Tome O, Sutterlin M, KrausTiefenbacher U (2008) Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer. Breast 17(6):617–622PubMedCrossRefGoogle Scholar
  77. Wyatt RM, Beddoe AH, Dale RG (2003) The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol 48:139–155PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Research Department of Surgery, Division of Surgery and Interventional ScienceUniversity College LondonHighgate HillLondon

Personalised recommendations